AMGEN INC (AMG.DE) Stock Price & Overview
FRA:AMG • US0311621009
Current stock price
The current stock price of AMG.DE is 293.1 EUR. Today AMG.DE is down by -1.69%. In the past month the price decreased by -2.58%. In the past year, price increased by 19.41%.
AMG.DE Key Statistics
- Market Cap
- 158.183B
- P/E
- 15.78
- Fwd P/E
- 15.10
- EPS (TTM)
- 18.57
- Dividend Yield
- 2.89%
AMG.DE Stock Performance
AMG.DE Stock Chart
AMG.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to AMG.DE. When comparing the yearly performance of all stocks, AMG.DE turns out to be only a medium performer in the overall market: it outperformed 54.01% of all stocks.
AMG.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to AMG.DE. AMG.DE scores excellent on profitability, but there are concerns on its financial health.
AMG.DE Earnings
On February 3, 2026 AMG.DE reported an EPS of 5.29 and a revenue of 9.87B. The company beat EPS expectations (9.56% surprise) and beat revenue expectations (2.11% surprise).
AMG.DE Forecast & Estimates
43 analysts have analysed AMG.DE and the average price target is 304.46 EUR. This implies a price increase of 3.88% is expected in the next year compared to the current price of 293.1.
For the next year, analysts expect an EPS growth of 4.51% and a revenue growth 4.12% for AMG.DE
AMG.DE Groups
Sector & Classification
AMG.DE Financial Highlights
Over the last trailing twelve months AMG.DE reported a non-GAAP Earnings per Share(EPS) of 18.57. The EPS increased by 10.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.98% | ||
| ROA | 8.51% | ||
| ROE | 89.06% | ||
| Debt/Equity | 5.78 |
AMG.DE Ownership
AMG.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 29.8 | 42.737B | ||
| ARGX | ARGENX SE | 29.42 | 42.687B | ||
| 22UA | BIONTECH SE-ADR | N/A | 23.644B | ||
| ABVX | ABIVAX SA | N/A | 7.77B | ||
| 2X1 | ABIVAX SA | N/A | 7.751B | ||
| GXE | GALAPAGOS NV | N/A | 1.641B | ||
| GLPG | GALAPAGOS NV | N/A | 1.626B | ||
| NANO | NANOBIOTIX | N/A | 1.275B | ||
| PHARM | PHARMING GROUP NV | 47.86 | 1.029B | ||
| PHGN | PHARMING GROUP NV | 48.32 | 1.028B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 997.606M | ||
| 6IV | INVENTIVA SA | N/A | 990.777M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About AMG.DE
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 31,500 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Company Info
IPO: 1983-06-17
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA US
Employees: 31500
Phone: 18009279800
AMGEN INC / AMG.DE FAQ
What does AMGEN INC do?
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 31,500 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Can you provide the latest stock price for AMGEN INC?
The current stock price of AMG.DE is 293.1 EUR. The price decreased by -1.69% in the last trading session.
Does AMG stock pay dividends?
AMGEN INC (AMG.DE) has a dividend yield of 2.89%. The yearly dividend amount is currently 7.64.
What is the ChartMill technical and fundamental rating of AMG stock?
AMG.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Which stock exchange lists AMG stock?
AMG.DE stock is listed on the Frankfurt Stock Exchange exchange.
Can you provide the number of employees for AMGEN INC?
AMGEN INC (AMG.DE) currently has 31500 employees.